New drug ABBV-722 tested in humans for first time
NCT ID NCT06673238
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This is a first-in-human study to see if ABBV-722 is safe and how the body handles it. About 95 healthy adults will receive either the drug or a placebo. The goal is to check for side effects and measure drug levels in the blood, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-722
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Acpru /Id# 270279
Grayslake, Illinois, 60030, United States
-
Altasciences Clinical Los Angeles /ID# 280183
Cypress, California, 90630, United States